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Abstract:  Protease domains within toxins typically act as the primary effector domain 
within target cells. By contrast, the primary function of the cysteine protease domain 
(CPD) in Multifunctional Autoprocessing RTX-like (MARTX) and Clostridium  sp. 
glucosylating toxin families is to proteolytically cleave the toxin and release its cognate 
effector domains. The CPD becomes activated upon binding to the eukaryotic-specific 
small molecule, inositol hexakisphosphate (InsP6), which is found abundantly in the 
eukaryotic cytosol. This property allows the CPD to spatially and temporally regulate toxin 
activation, making it a prime candidate for developing anti-toxin therapeutics. In this 
review, we summarize recent findings related to defining the regulation of toxin function 
by the CPD and the development of inhibitors to prevent CPD-mediated activation of 
bacterial toxins. 
Keywords: cysteine protease domain (CPD); MARTX toxin; glucosylating toxin (GT); 
inositol hexakisphosphate (InsP6); glucosyltransferase (Glc); structure activity relationship 
(SAR) 
 
1. Autoproteolytic Activation of Bacterial Toxins 
Many bacterial toxins whose targets are within host cells require proteolytic activation for their 
function. Whereas most toxins, such as cholera toxin and anthrax toxin, are cleaved by a eukaryotic 
cell protease, a subset of bacterial toxins is autoproteolytically activated by an internal cysteine 
protease domain (CPD). The CPD is found within two multidomain toxin families: the Multifunctional 
Autoprocessing RTX-like toxins (MARTX) toxins and the Clostridium sp. glucosylating toxins (GTs) 
(Figure 1a and b). Because the CPD is directly activated by the eukaryotic-specific small molecule 
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inositol hexakisphosphate (InsP6), the CPD acts as a biosensor that appears to allow for temporal and 
spatial regulation of toxin activation. Once toxins translocate across eukaryotic cell membranes, the 
CPD binds to InsP6 within the cell (KD ~ 1–2 µM) [3–5] and induces toxin autoprocessing. Cleavage 
of the toxins by the CPD releases cognate effector domains and subsequently enhances toxin function  
[6–9]. Importantly, InsP6 is found at concentrations between 5–100 µM within the cytosol of 
mammalian cells, exhibits a long half-life in cells, and may be localized to cellular membranes and the 
nucleus [10–12]. 
1.1. MARTX toxins 
The MARTX toxins are a newly discovered family of toxins that are encoded in the genomes of a 
number of Gram-negative bacteria [14]. Although only a few toxin members have been studied to date, 
MARTX toxins have been shown to modulate the virulence of Vibrio cholerae, Vibrio vulnificus, and 
Vibrio anguillarum. The MARTX toxin of V. cholerae, the causative agent of cholera, is produced by 
nearly all clinical and environmental isolates of V. cholerae [15–17]. Although it is not cytotoxic, it 
induces cell rounding and enhances colonization in a mouse model of infection [18–21]. By contrast, 
MARTX toxins of the marine pathogens V. vulnificus and V. anguillarum are cytotoxic and function as 
key virulence factors [22–24].  
MARTX toxins are some of the largest bacterial proteins identified to date, with molecular weights 
often in excess of 450 kDa [14]. They are characterized by conserved N- and C-terminal repeat regions 
with similarity to RTX toxins that flank a central effector domain region (Figure 1a). These repeat 
regions have been proposed to form a pore that allows the central effector region to autotranslocate 
across host cell membranes [18]. While the composition of the central region varies across MARTX 
toxin family members, the most C-terminal effector of MARTX toxins is always the InsP6-sensing 
cysteine protease domain (CPD). In V. cholerae MARTX toxin, the best characterized family member, 
the CPD cleaves the toxin at multiple sites to release discrete effector domains   
(Figure 1c) [9,25]. 
Aside from the CPD, the activities of most MARTX effector domains remain uncharacterized. The 
functions of only two other effector domain functions have been identified to date; both these domains 
are found within V. cholerae MARTX toxins and disrupt host cell actin dynamics. The actin 
crosslinking domain (ACD) has homology to ATP-dependent ligases and covalently crosslinks actin 
monomers together through an atypical glutamate-lysine crosslink [26–29]. As a result, the ACD 
prevents growth of actin filaments and depletes the monomeric actin pool, which leads to cell rounding 
due to destruction of the actin cytoskeleton. The Rho Inactivating Domain (RID) domain inhibits small 
Rho GTPase activity through an as yet undefined mechanism [30].  
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Figure 1. Autoproteolytic activation of MARTX and glucosylating toxin families by the 
CPD. (a) Domain organization of V. cholerae MARTX toxin. Conserved glycine-rich 
repeat regions in the N- and C-termini of MARTX toxins (MARTX conserved, red); actin 
crosslinking domain (ACD, orange); Rho-inactivating domain (RID, green); / hydrolase 
domain (/, purple), cysteine protease domain (CPD, pink). Cleavage sites are shown.  
(b) ABCD domain organization of C. difficile glucosylating toxins. A: Glucosyltransferase 
(Glc) “activity” domain; B: receptor “binding” domain; C: cysteine protease “cutting” 
domain; and D: hydrophobic translocation “delivery” domain. Cleavage site in TcdB is 
marked (c) Schematic model for CPD-mediated activation of V. cholerae MARTX toxin. 
Upon encountering a eukaryotic cell, the N- and C-terminal MARTXVc conserved regions 
insert into the plasma membrane and form a pore that permits translocation of the toxin 
central region across the cell membrane. Following toxin entry, the CPD binds inositol 
hexakisphosphate (InsP6, starburst), resulting in activation of its protease activity. The 
CPD first cleaves at Leu3441, the preferred autoprocessing site, then Leu2447, followed by 
Leu3099 (least preferred cleavage site) [9]. Processing of MARTXVc by the CPD releases 
the RID and (/) domains into the cytosol, while the ACD and CPD remain tethered to 
the membrane. Cleavage of MARTXVc, particularly at Leu2447, activates the actin 
crosslinking activity of the ACD. (d) Schematic model for CPD-mediated activation of 
Clostridium sp. glucosylating toxins. Binding of the toxins to unidentified receptors results 
in their uptake by receptor-mediated endocytosis. Acidification of the early endosome 
triggers toxin translocation of the Glc domain (triangle). This is the only part of the protein 
released into the cytosol, presumably due to CPD-mediated autoproteolysis [13]. Whether 
the CPD itself is translocated, and when and where it is activated by InsP6 (starburst) is 
unknown, although it likely occurs on the cytosolic face of the endosomal membrane.  
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1.2. Clostridium sp. glucosylating toxins 
Similar to MARTX toxins, Clostridium sp. glucosylating toxins are multidomain toxins that alter 
target cell cytoskeletal dynamics in a manner dependent on CPD-mediated toxin autoprocessing 
(Figure 1b and d). Glucosylating toxins are large (~250 kDa) proteins with an ABCD toxin structure 
(A, biological activity; B, binding; C, cutting; D, delivery) [7,31,32]. The “biological activity” (A) is 
conferred by the N-terminal glucosyltransferase (Glc) domain, which glucosylates Rho GTPases (such 
as RhoA and Ras) at a conserved Thr residue [33,34]. This covalent modification prevents Rho   
GTP-GDP exchange and irreversibly inhibits Rho GTPase function, leading to disruption of epithelial 
barrier junctions, inhibition of Rho-mediated signaling, and ultimately cell death and inflammation 
[35]. The “binding activity” (B) of GTs is mediated by the C-terminal repeat region, which forms a 
solenoid structure that probably binds sugar moieties on cell surface receptors (the identity of which 
has not been determined). The toxins are then taken up by receptor-mediated endocytosis.  
As “short-trip” toxins, acidification of the early endosomal compartment induces conformational 
changes in GTs that results in membrane insertion and toxin translocation. The central, hydrophobic 
region is thought to confer this “delivery activity” (D) [36]. While the mechanism by which this occurs 
remains unclear, the central region likely mediates translocation of the Glc domain across the 
endosomal membrane into the target cell cytosol. The CPD domain presumably is also transferred, but 
this has not been directly tested. Nevertheless, binding of InsP6 to the CPD (either in the endosome or 
in the host cytosol) results in CPD activation and cleavage of GTs at the Glc domain-CPD junction 
[3,37,38]. This “cutting” (C) event releases the Glc domain from the endosome, an event that 
presumably improves access of the Glc domain to its Rho GTPase substrates at the membrane. 
The glucosylating toxins (GTs) are produced by select Clostridium sp. pathogens, which are Gram-
positive, anaerobic, spore-forming bacteria. Members of the GT family include TcdL and TcdH of  
C. sordellii, TcnA of C. novyi, and C. perfringens types B and C, but the prototypical members are 
TcdA and TcdB of C. difficile. This latter bacterium is of particular interest as it is the leading cause of 
nosocomial diarrhea worldwide and is associated with significant morbidity and cost in health care-
associated settings [39,40]. The glucosylating toxins TcdA and TcdB are the primary causes of   
C. difficile infection (CDI), with TcdB being the more active of the two toxins and essential for 
virulence [41]. The relevance of these toxins to disease is underscored by the observation that a strain 
that hyper-produces TcdA and TcdB causes more frequent and severe cases of CDIs [40,42]. Thus, the 
development of inhibitors that can inhibit TcdA and TcdB function or activation should have 
considerable therapeutic utility.  
2. Autoprocessing Cysteine Protease Domains 
Although MARTX and GT toxin families differ in their activities and domain organization, they 
share a common cysteine protease domain (CPD) that proteolytically processes toxin family members. 
Despite differing in 60% of their amino acid residues, both MARTX and GT CPDs have a similar 
overall fold that resembles a canonical caspase-like fold (Figure 2a and b). As clan CD proteases 
(MEROPS classification) [43], both bacterial CPDs and caspases have a central -sheet that is 
surrounded by -helices [44]. Unlike the caspases, however, bacterial CPDs contain an InsP6 binding 
site and a region termed the -flap (described below). Structures of both MARTX and TcdB CPDs Toxins 2010, 2                                       
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reveal that the InsP6 binding site is comprised of numerous positively charged residues that trap a 
single negatively-charged InsP6 molecule [4,25,45]. Interestingly, the mechanism of InsP6 binding 
differs slightly between Tcd and MARTX CPDs, with InsP6 lying flat on the surface of the protease in 
V. cholerae MARTX CPD, and InsP6 being wedged into the side of TcdA CPD (Figure 2c and d) 
[45]. Both proteases, however, have similar low micromolar affinities for InsP6 [4,5,37]. 
Figure 2. Structure of bacterial CPDs. Ribbon structure of (a) V. cholerae MARTX CPD 
(PDB ID: 3EEB) and (b) C. difficile TcdA CPD (PDB ID: 3HO6). Electrostatic surface 
potential of (c) V. cholerae MARTX CPD and (d) C. difficile TcdB CPD as viewed from 
above the InsP6 binding site. Blue denotes positively charged surface; red denotes 
negatively charged surface. InsP6 is shown in the binding site as a stick model. Note that 
the orientation of the InsP6 molecule differs between the two structures. 
 
Notably, the InsP6 binding site is physically distinct from the active site, indicating that InsP6 likely 
functions as an allosteric activator of bacterial CPDs. Although a number of studies have shown that 
InsP6 binding improves access of the CPD to its substrates and inhibitors [3,4,25], the mechanism by 
which InsP6 binding is communicated to the active site has not been fully characterized. Current work 
suggests that the -flap region - the second structural feature in which bacterial CPDs differ from other 
clan CD proteases - transduces the InsP6 binding to the active site. Mutation of key residues in the  
-flap disrupt CPD function [4,5,37,45], and residues in this region have been shown to be resistant to 
limited proteolysis in the presence of InsP6 [25]. This latter result suggests that InsP6 binding induces 
stabilization of the -flap in the activated protease. Interestingly, the -flap region of TcdA CPD is 
larger than that of V. cholerae CPD, with TcdA CPD containing an additional alpha-helix [45]; the 
functional significance of this addition is unknown.  
This mechanism of allosteric regulation by a small metabolite is unique among proteases. 
Nevertheless, bacterial CPDs exhibit many similarities in substrate recognition to clan CD proteases. 
In particular, like the caspases, the substrate specificity of MARTX CPDs is governed by the P1 Toxins 2010, 2                                       
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residue, the amino acid immediately N-terminal to the scissile bond [9,25,46–48]. Just as caspases 
cleave almost exclusively after P1 Asp residues, bacterial CPDs appear to cleave exclusively after P1 
Leu residues: all known MARTX and GT toxin autoprocessing sites occur after Leu residues 
[3,9,25,49]. In addition, like the caspases, MARTX CPDs appear to exhibit a preference for a small 
amino acid in the P1’ position, the residue immediately C-terminal to the scissile bond. A comparison 
of known and inferred cleavage sites within MARTX and GT toxins suggests that small residues in the 
P1’ position are favored (Figure 3). Furthermore, the CPD has been shown to cleave more efficiently 
when the P1’ residue is an Ala versus a Ser residue, while the presence of a bulky P1’ Leu residue is 
sufficient to abrogate CPD-mediated processing [9].  
Figure 3. Sequence logo representation of MARTX and GT CPD consensus cleavage 
site. The sequence logo was created using natural MARTX CPD cleavage sites mapped by 
intact mass spectrometry [9] and cleavage sites mapped and/or inferred in GT CPDs 
[38,49], see http://weblogo.berkeley.edu. The dashed line indicates the   
scissile bond.  
 
3. Development of Inhibitors of Bacterial CPD Protease Activity 
The restraints on substrate specificity determined by cleavage site comparisons are also observed in 
studies with MARTX CPD inhibitors [9]. Inhibitors of V. cholerae MARTX CPD processing were 
recently identified in a screen of a focused library of cysteine protease inhibitors. All CPD inhibitors 
derived from the screen contain a Leu in the P1 position, the residue immediately N-terminal to the 
scissile bond. They were also all functionalized with an aza-epoxide group, which reacts with the 
caspases [50]. The screen produced a small structure-activity relationship (SAR) series that shows 
remarkable similarities to an SAR series previously performed on the caspases. In particular, the regio- 
and stereochemistry at the epoxide moiety influences inhibitor potency for both V. cholerae CPD and 
caspase-3, with S,S > trans > R,R [9,51].  
The crystal structure of V. cholerae CPD bound to the most potent inhibitor from the screen 
(JCP598, Z-LL-azaL-EP, Figure 4a) provided the most convincing evidence that MARTX CPDs and 
caspases share similar mechanisms of substrate recognition and catalysis [9]. In both the V. cholerae 
CPD and caspase-3 structures bound to aza-epoxide inhibitors, the catalytic Cys of V. cholerae CPD Toxins 2010, 2                                       
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attacks on the C3 position of the expoxide rather than the C2. Furthermore, the catalytic residues of  
V. cholerae MARTX CPD and caspase-3 exhibit similar geometries around the P1-P1’ peptide bond, 
and the S1 binding pockets (that recognize the P1 residue) are similarly aligned. Indeed, the S1 pocket 
of V. cholerae MARTX CPD forms a deep, hydrophobic cavity that perfectly accommodates a Leu 
residue (Figure 4b), and residues that form this S1 pocket are conserved across MARTX and GT 
CPDs. Notably, the structure of aza-epoxide inhibited V. cholerae MARTX CPD is essentially 
superimposable with the recently solved structure of the uncleaved form of the protease. This 
uncleaved form carries the native P1 Leu and non-native TEV protease cleavage site [25]. The P1 Leu 
residues of both MARTX CPD structures are similarly aligned, while mutational analyses of the P2 
site also support the conclusion that the primary substrate specificity determinant is a P1 Leu [25].  
As observed with the natural cleavage substrates of MARTX toxins, the P2 and P3 positions of the 
inhibitors do not strongly contribute to substrate recognition [9]. For example, no difference in 
inhibitor potency was observed between a Cbz-Leu-Leu-azaLeu (Z-LLaL-EP) epoxide inhibitor and 
Cbz-Asp-Ala-azaLeu (Z-EAaL-EP) epoxide inhibitor. Furthermore, the S2 and S3 sub-sites in the 
crystal structure of inhibitor-bound MARTX CPD do not make contacts with the P2 and P3 side chains 
of the inhibitor; rather, the protease interacts with the peptide backbone of the inhibitor. These 
conclusions are consistent with SAR series results, indicating that inhibitors carrying P2 and P3 
residues were more potent than inhibitors with only a single P1 Leu.  
The functional group of the P1 Leu inhibitors also affects inhibitor potency. Whereas inhibitors 
with a P1 Leu and acyloxymethylketone (AOMK) functional group, which reacts with caspases [52], 
block the activity of V. cholerae MARTX CPD, inhibitors with the same peptide sequence as JCP598 
(but different reactive groups) do not inhibit CPD function [9]. Specifically, MG132, a common 
proteasome inhibitor (Cbz-LLL-aldehyde) and Z-L3VS (Cbz-LLL-vinyl sulfone) do not block   
V. cholerae CPD autocleavage. The lack of inhibitory activity of Z-L3VS may reflect the preference of 
MARTX CPDs for small P1’ residues in the consensus cleavage site sequence. Indeed, the S1’ subsite 
(which interacts with the P1’ residue) is flat and featureless and may not accommodate large 
constituents in the P1’ position. Nevertheless, making contacts with the S1’ subsite would appear to be 
important for inhibitor potency given the lack on inhibitor activity of MG132. 
Although the aza-epoxide inhibitors identified in the screen are designed to covalently inhibit 
cysteine proteases, they failed to irreversibly react with V. cholerae MARTX CPD under standard 
assay conditions (A. Shen, unpublished data). The apparent slow reactivity of V. cholerae MARTX 
CPD with the aza-epoxide inhibitors may reflect the rapid rate with which InsP6 likely binds to and 
dissociates from the CPD relative to inhibitor binding. In contrast, when the aza-epoxide inhibitor was  
co-crystallized with V. cholerae CPD in the presence of InsP6, the inhibitor likely had sufficient time 
to react with the enzyme constrained in the crystal lattice. The lack of reactivity of the aza-epoxide 
inhibitors may also reflect the need for optimization of substrate binding or electrophile reactivity to  
V. cholerae CPD. To the latter point, functionalized alkylating agents have been shown to react with 
the sole catalytic Cys of V. cholerae CPD in a manner that is enhanced by the presence of InsP6 [9,25]. 
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Figure 4. Chemical inhibition of MARTX CPD activity. (a) Structures of the most 
potent MARTX CPD inhibitors. Navy blue indicates aza-linkage; purple highlights P1 
Leu, and orange denotes electrophile warhead. (b)  Surface topology of activated 
MARTXVc CPD bound to an aza-peptide epoxide inhibitor. Hydrophobic residues in the 
substrate binding cleft are in yellow. The aza-peptide epoxide inhibitor (JCP598) is shown 
as a stick model bound in the substrate binding pocket. The N-terminus is shown as a grey 
ribbon, terminating at Ile3437 and highlighting the threading of this region along the 
surface of the core domain.  
 
Nevertheless, MARTX CPD inhibitors are capable of reducing CPD-mediated processing of 
MARTX toxin during growth of V. cholerae in broth culture [9]. While the inhibitors are not effective 
at preventing CPD autocleavage in the native toxin, they do prevent processing of the toxin by the 
CPD at distal sites. Although they have limited potency on the native toxin, the CPD inhibitors were 
useful in determining the relative affinity of the CPD for its different cleavage sites, which correlated 
the relative affinities determined using in vitro cleavage reactions. Notably, the inhibitors were also 
capable of preventing MARTX toxin activity (specifically actin crosslinking activity) during 
intoxication of target cells. The aza-epoxide inhibitors were the most potent, since they were more cell 
permeable than the AOMK inhibitors; Cbz-LLaL-EP was the most cell permeable inhibitor. While the 
specificity of these inhibitors in complex mixtures still needs to be assessed, these results strongly 
suggest that CPD inhibitors can prevent the autoproteolytic activation of MARTX toxins inside target 
cells. Thus, the MARTX CPD inhibitors provide a starting point for the development of active site 
inhibitors of MARTX CPDs and potentially GT CPDs (given that S1 residues in MARTX and GT 
CPDs appear to be conserved). Toxins 2010, 2                                       
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4. Requirement of CPD-Mediated Processing for Toxin Activity  
Although CPD-mediated processing of V. cholerae MARTX and C. difficile Tcd toxins is necessary 
for optimal toxin function, it is not absolutely required. Toxins carrying mutations in the catalytic Cys 
of both V. cholerae MARTX and C. difficile TcdB CPDs can still exert cytopathic effects on cells, but 
the toxin activity is significantly decreased [3,4,6,8]. Why proteolytic cleavage enhances effector 
domain function has not been characterized. The known substrates of both V. cholerae MARTX and 
Tcd toxins are often localized to the host cell plasma membrane, so it has been hypothesized that  
CPD-mediated processing improves access of toxin effector domains to their substrates.  
C. difficile glucosylating toxins are cleaved by the CPD after a single conserved Leu at the 
glucosyltransferase (Glc) domain-CPD junction [3,49]. This cleavage event releases the Glc domain 
from the endosomal membrane into the cytosol, while the remainder of the toxin remains membrane-
associated (Figure 1b, [13,49]). This cleavage event likely enhances access of the Glc domain to its 
Rho GTPase substrates at the plasma membrane given that a membrane localization domain (MLD) 
was recently identified in its N-terminus [53]. This MLD was recently shown to be sufficient to 
mediate plasma membrane localization, with enrichment observed at cell-cell junctions in particular. 
An analysis of the localization of the Glc domain and its activity in toxins carrying mutations of the 
CPD cleavage site and/or CPD catalytic residues will be important for determining the precise function 
of the CPD in regulating Clostridium sp. glucosylating toxin activation. Such analyses will be greatly 
facilitated with the advent of new tools for manipulating C. difficile genetically [54].  
In contrast with the glucosylating toxins, the precise mechanism by which CPD-mediated 
processing increases effector domain activity in MARTX toxins is less apparent. Whereas the CPD 
cleaves Clostridium sp. glucosylating toxins at a single site, the CPD processes MARTX toxins at 
multiple sites. The cleavage sites all occur after a Leu residue and are found at interdomain boundaries 
predicted to be disordered [9]. The identity of cleavage sites was confirmed by mutational analyses 
with both recombinant and native MARTX toxin. These analyses indicate that these three sites are the 
primary cleavage sites in the toxin, although a small amount of second site processing of these toxins 
can be observed in a mutant in which all three P1 Leu cleavage sites have been mutated to Ala 
residues [9]. It should be noted that a fourth cleavage site was mapped by Prochazkova et al. [25] using 
N-terminal sequencing of in vitro cleavage reactions of recombinant V. cholerae MARTX toxin. 
However, extensive Western blot analyses of wildtype and cleavage site mutants indicate that this site 
is not physiologically relevant in the native toxin [9]. 
CPD-mediated processing separates the actin crosslinking domain (ACD), Rho-inactivating domain 
(RID), and / hydrolase domains (Figure 1a). While these cleavage events should liberate the RID 
and / hydrolase domains from the membrane, both the ACD and CPDs are predicted to remain 
tethered to the membrane. The membrane localization of these domains may be important to their 
function, perhaps by optimizing access of the ACD and CPD to their substrates. Indeed, the CPD is 
always found adjacent to the C-terminal MARTX conserved region, while the ACD in other MARTX 
toxins is always found just downstream of the N-terminal MARTX conserved region. Tethering of the 
CPD to the membrane likely facilitates processing of the toxin at distal sites, by keeping the substrates 
in close proximity. The dependence of the ACD domain on CPD-mediated processing remains less 
clear. Studies of V. cholerae cleavage site mutants indicate that processing of the ACD-RID junction is Toxins 2010, 2                                       
 
 
972
necessary for optimal ACD activity [9]. Nevertheless, cleavage at any site would appear to stimulate 
ACD activity, although why this is observed is unknown. Further studies of the ACD and its 
interaction with its substrate will likely provide important insight into the functional requirements of 
this domain and the role of CPD-mediated processing in stimulating its activity. 
The dependence of the remaining V. cholerae effector domains on CPD-mediated processing has 
not yet been tested. Further analysis of the biochemical functions of the RID and / hydrolase 
domains will likely provide insight into any role that the CPD may play in activating the function of 
these effector domains. These studies will require that a function for the / hydrolase domain be 
determined, since there is no information on the activity or localization of this domain. Likewise, a 
more thorough characterization of the function of the RID domain would contribute to an 
understanding of the role of proteolysis in activating RID function. Although the RID domain has been 
shown to disrupt Rho GTPase function [30], the mechanism by which this occurs is unknown. CPD-
mediated processing should liberate the RID domain from MARTX toxin at the membrane. However, 
a recent study suggests that the RID should remain associated with the membrane through its   
N-terminal MLD domain [53], which preferentially localizes to cell-cell junctions and is necessary for 
optimal RID activity. If these sites are where the putative RID substrate is enriched, CPD-mediated 
cleavage may similarly enhance access of the RID domain to its substrates. Indeed, localization of the 
RID to the membrane has been shown to significantly increase its ability to induce cell rounding [53]. 
Alternatively, CPD-mediated processing may function to produce free N- and C-termini that are 
necessary for optimal RID enzymatic activity. 
5. Conclusions and Perspectives  
Analyses of V. cholerae MARTX toxin will likely be transferable to other MARTX toxins, which 
typically contain RID, ACD, and/or / domains. Studies of other MARTX toxins will be greatly 
enhanced by mapping CPD cleavage sites, since these will define effector domain boundaries and 
contribute to a more global understanding of the role of this protease domain in toxin regulation. In 
general, the CPD appears to function analogously to viral polyprotein processing proteases such as 
those produced by picornaviruses (such as poliovirus and Hepatitis C). Viruses often use a conserved 
internal protease domain to proteolytically process the single polyprotein precursor into discrete 
functional domains that mediate viral replication and assembly [55]. Notably, both viral and CPD 
autoprocessing proteases exhibit a high degree of sequence specificity but poor transcleavage activity 
[56]. As a result, these proteases do not appear to cleave substrates in their target host cells. Consistent 
with this proposal, a MARTX toxin that carries only the CPD in the central translocated region does 
not overtly affect the morphology of target cells exposed to this mutant toxin (A. Shen, unpublished 
data), strongly suggesting that the CPD does not have many substrates within target cells aside from 
the MARTX toxins.  
Nevertheless, just as viral polyprotein processing enzymes have been prime targets for therapeutic 
intervention [57], the CPDs of both MARTX and Clostridium sp. glucosylating toxins are excellent 
targets for drug design. The C. difficile glucosylating toxin CPDs are particularly good candidates 
because TcdA and TcdB toxins are the primary factors responsible for C. difficile-associated disease 
[40]. Given that C. difficile infections are often promoted by antibiotic administration, targeting Toxins 2010, 2                                       
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virulence rather than viability will likely be the most effective strategy for controlling C. difficile-
associated disease. Likewise, given that MARTX toxins are comprised of multiple effector domains 
that vary among toxin family members [14], targeting the conserved CPD domain will likely be a more 
effective strategy at inhibiting MARTX toxin activation that developing inhibitors against each 
domain. MARTX CPD inhibitors would have particular applicability in aquaculture settings where 
infection by V. anguillarum and V. vulnificus infection of fish and bivalves is particularly costly to the 
seafood industry. 
The identification of the first active site inhibitors of bacterial CPDs has provided an excellent 
starting point for the optimization of inhibitors with greater potency, selectivity, and stability, and the 
structure of inhibitor-bound CPD may serve as a platform for inhibitor modeling. An alternative 
strategy to targeting the active sites of these proteases may be to prevent the activation of bacterial 
CPDs by restraining their conformational mobility and thus allosteric activation [58]. Thus, a better 
understanding of the mechanism of CPD activation will likely lead to more effective strategies for 
preventing toxin activation. 
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